alexa Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related Diabetes

Anery Patel1*, Heather Spain2 and Whitney Goldner1

1Department of Internal Medicine, Division of Diabetes, Endocrine and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska, USA

2College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

*Corresponding Author:
Anery Patel
Endocrinology Fellow, Department of Internal Medicine
Division of Diabetes, Endocrinology and Metabolism
984120 Nebraska Medical Center, Omaha, Nebraska, USA
Tel: 402-559-6876
Fax: 402-559-9003
E-mail: [email protected], [email protected]

Received date: October 28, 2014; Accepted date: February 21, 2015; Published date: February 25, 2015

Citation: Patel A, Spain H, Goldner W (2015) Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related Diabetes. J Diabetes Metab 6:501. doi: 10.4172/2155-6156.1000501

Copyright: © 2015 Patel A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Cystic Fibrosis Related Diabetes (CFRD) is the most common comorbidity in patients with Cystic Fibrosis (CF) and its incidence is rising. CFRD is associated with a decline in clinical status and six-fold increased mortality in patients with CF, the outcomes of which can be improved with early diagnosis and proper treatment. While current treatment guidelines recommend the use of insulin monotherapy to treat CFRD and do not recommend oral agents, these guidelines were published before the use of dipeptidyl peptidase-4 inhibitors (DPP-4). We present two cases of CFRD patients who were successfully managed with DPP-4 inhibitors both inpatient as well as outpatient.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords